Submission of intimation of allotment of equity shares.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astal Laboratories has made two allotments on January 14, 2026. First, 3,04,25,632 equity shares at Rs. 91 each (premium of Rs. 81 over the Rs. 10 face value) were issued to 134 non-promoter allottees as consideration other than cash for acquiring equity shares of Sriven Pharmachem India Private Limited, which will become a wholly owned subsidiary. Second, 10,20,000 equity shares were allotted at Rs. 40 each (premium of Rs. 30) upon conversion of an equal number of warrants by 9 non-promoter holders, bringing in Rs. 3.06 crore as the remaining 75% payment. After both allotments, the company's paid-up equity capital has risen from about Rs. 10.77 crore to Rs. 42.22 crore, a nearly 4x increase.
The Sriven Pharmachem acquisition is a share-swap deal that brings a new subsidiary into the company without using cash, expanding its business footprint but also significantly diluting existing shareholders. Warrant conversion brings in modest cash but adds further dilution. Expect increased share count and possible volatility as lock-in periods expire.